心力衰竭患者ACEI与β受体阻滞剂上调的决定因素与临床结局
BIOSTAT-CHF前瞻性研究纳入11个欧洲国家69个中心的2516例心衰患者,分析2100例HFrEF患者ACEI/ARB和β受体阻滞剂的上调情况,随访中位21个月。22%达到ACEI/ARB推荐剂量,12%达到β受体阻滞剂推荐剂量;未达推荐剂量50%与死亡和/或心衰住院风险增加相关。
要点
- 22%患者达到ACEI/ARB推荐剂量,12%达到β受体阻滞剂推荐剂量
- 未达推荐剂量50%与死亡和/或心衰住院风险增加相关
- 达到推荐剂量50-99%与≥100%的患者风险相当
核心结论
- 接受ACEI/ARB和β受体阻滞剂推荐剂量不足50%的HFrEF患者,与达到≥100%推荐剂量的患者相比,似乎有更高的死亡和/或心衰住院风险。
研究设计与样本
- BIOSTAT-CHF为前瞻性研究,纳入11个欧洲国家69个中心的2516例心衰患者,选择治疗次优且预期并鼓励启动或上调治疗的患者。
- 排除上调期间死亡患者(n=151)和左室射血分数>40%患者(n=242),最终分析2100例HFrEF患者(76%男性,平均年龄68±12岁)。
- 中位随访21个月。
主要发现
- 22%患者达到ACEI/ARB推荐治疗剂量,12%患者达到β受体阻滞剂推荐治疗剂量。
- 欧洲国家之间存在明显差异。
- 未达到ACEI/ARB和β受体阻滞剂推荐剂量50%与死亡和/或心衰住院风险增加相关。
- 达到ACEI/ARB和/或β受体阻滞剂推荐剂量50-99%的患者与达到≥100%的患者相比,死亡和/或心衰住院风险相当。
- 因症状、副作用和非心脏器官功能障碍而未达推荐剂量的患者死亡率最高(ACEI/ARB:HR 1.72,95%CI 1.43-2.01;β受体阻滞剂:HR 1.70,95%CI 1.36-2.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers. METHODS AND RESULTS: BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died during the uptitration period (n = 151) and patients with a LVEF > 40% (n = 242) were excluded. Median follow up was 21 months. We studied 2100 HFrEF patients (76% male; mean age 68 ±12), of which 22% achieved the recommended treatment dose for ACE-inhibitor/ARB and 12% of beta-blocker. There were marked differences between European countries. Reaching <50% of the recommended ACE-inhibitor/ARB and beta-blocker dose was associated with an increased risk of death and/or heart failure hospitalization. Patients reaching 50-99% of the recommended ACE-inhibitor/ARB and/or beta-blocker dose had comparable risk of death and/or heart failure hospitalization to those reaching ≥100%. Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had the highest mortality rate (for ACE-inhibitor/ARB: HR 1.72; 95% CI 1.43-2.01; for beta-blocker: HR 1.70; 95% CI 1.36-2.05). CONCLUSION: Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers seemed to have a greater risk of death and/or heart failure hospitalization compared with patients reaching ≥100%.
引用
- Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017. PMID: 28329163. doi:10.1093/eurheartj/ehx026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。